[1] 翟凤英. 中国人面临的五大营养问题——来自全国第四次营养调查的一线报告. 企业标准化, 2008: 30-31.
[2] Fan J G. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol, 2013, 28: 11-17.
[3] 郑秋甫. Omega-3 多不饱和脂肪酸的研究进展. 中华保健医学杂志, 2011, 13: 357-360.
[4] Bouzianas DG, Bouziana SD, Hatzitolios AI. Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. Nutr Rev, 2013, 71: 753-771.
[5] 廖灵旋, 于昊, 黄建忠. 多不饱和脂肪酸合成途径研究进展. 微生物学杂志, 2014, 3: 021.
[6] 孙翔宇, 高贵田, 段爱莉, 等. 多不饱和脂肪酸的研究进展. 食品工业科技, 2012, 33: 418-423.
[7] 田宇, 王忠彦. DHA 和 EPA 的生理功能及研究进展. 四川食品与发酵, 2003, 39: 44-47.
[8] Benistant C, Achard F, Slama SB, et al. Docosapentaenoic acid (22∶5, n-3)∶metabolism and effect on prostacyclin production in endothelial cells. Prostaglandins Leukot Essent Fatty Acids, 1996, 55: 287-292.
[9] 王萍, 张银波, 江木兰. 多不饱和脂肪酸的研究进展. 中國油脂, 2008, 33: 42-46.
[10] 贾燕, 陈雄, 王芬. 海狗油 ω-3 多不饱和脂肪酸胶丸治疗非酒精性脂肪肝的疗效研究. 實用預防醫學, 2010, 17: 1833-1834.
[11] 陈榕, 郭清, 朱文静, 等. ω-3 多不饱和脂肪酸胶丸对非酒精性脂肪肝患者的治疗作用. 世界华人消化杂志, 2008, 16: 2002-2006.
[12] 荀运浩, 施军平. 2014 年非酒精性脂肪性肝病诊治进展. 实用肝脏病杂志, 2015, 18: 6-9.
[13] 南月敏. 非酒精性脂肪性肝病发病机制的研究进展. 现代消化及介入诊疗, 2009, 14: 169-172.
[14] Li Y, Chen D. The optimal dose of omega-3 supplementation for non-alcoholic fatty liver disease. J Hepatol, 2012, 57: 468-469.
[15] Shapiro H, Tehilla M, Attal-Singer J, et al. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr, 2011, 30: 6-19.
[16] Vega GL, Chandalia M, Szczepaniak LS, et al. Effects of N-3 fatty acids on hepatic triglyceride content in humans. J Investig Med, 2008, 56: 780-785.
[17] Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis, 2008, 40: 194-199.
[18] Zhu FS, Liu S, Chen XM, et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol, 2008, 14: 6395-400.
[19] 伍金华, 周克元. 调节食物中ω-6和ω-3脂肪酸合适比例研究的进展. 国外医学:卫生学分册, 2006, 33:70-73.
[20] Parker HM, Johnson NA, Burdon CA, et al. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol, 2012, 56: 944-951.
[21] Musso G, Gambino R, Cassader M, et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology, 2010, 52: 79-104.
[22] Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther, 2006, 23: 1143-1151.
[23] Marzuillo P, Miraglia del Giudice E, Santoro N. Pediatric fatty liver disease: role of ethnicity and genetics. World J Gastroenterol, 2014, 20: 7347-7355.
[24] Simopoulos AP. Human requirement for N-3 polyunsaturated fatty acids. Poult Sci, 2000, 79: 961-970.
[25] 1Ristic′ V, Risti G. Role and importance of dietary polyunsaturated fatty acids in the prevention and therapy of atherosclerosis]. Med Pregl, 2002, 56: 50-53.
[26] 郑永才, 陈亮, 路富林,等. 运动疗法治疗非酒精性脂肪肝的临床疗效观察. 肝脏, 2015:51-53. |
